在线磁共振引导自适应五分割立体定向体部放疗治疗不可手术胰腺癌
中位随访16个月,晚期3级毒性2例(4.6%),中位总生存15.7个月,1年局部控制率84.3%。结论认为SMART可安全实施该消融剂量并取得较好疗效。
要点
- SMART每日在线自适应可实现胰腺癌50 Gy/5次消融剂量。
- 晚期3级毒性仅2例(4.6%),均为胃肠道溃疡。
- 中位总生存15.7个月,1年局部控制率84.3%。
核心结论
- SMART支持对不可手术胰腺癌实施50 Gy/5次消融剂量,毒性可控且疗效可观。
研究设计与样本
- 处方剂量50 Gy/5次(BED10 100 Gy),目标95%计划靶区覆盖95%处方剂量,优先满足危及器官硬性约束。
- 每日在线磁共振引导并台上重新优化。
主要发现
- 中位随访16个月(范围6.7-51.6)。
- 晚期毒性:3级2例(4.6%,胃肠道溃疡),2级3例(6.8%,十二指肠穿孔、胃窦溃疡、胃出血)。
- 35例(79.5%)肿瘤毗邻危及器官,5例(11.1%)侵犯危及器官。
- 93%的分次进行了重新优化。
- 中位总生存15.7个月(95%CI 10.2-21.2),1年与2年总生存率分别为68.2%和37.9%,1年局部控制率84.3%。
临床怎么用
- 对不可手术局部晚期胰腺癌可考虑SMART实现50 Gy/5次消融剂量。
- 治疗中需每日在线自适应并优先满足危及器官约束以控制毒性。
局限性
- 随访时间有限,中位16个月。
- 需进一步前瞻性试验验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has shown promise in delivering ablative doses safely. We sought to demonstrate the benefits of SMART using a 5-fraction approach with daily on-table adaptation. METHODS AND MATERIALS: Patients with locally advanced, nonmetastatic pancreatic adenocarcinoma were treated with 50 Gy in 5 fractions (biologically effective dose10 100 Gy) with a prescribed goal of 95% planning target volume coverage by 95% of prescription, prioritizing hard OAR constraints. Daily online adaptation was performed using magnetic resonance-guidance and on-table reoptimization. Patient outcomes, treatment factors, and daily adaptation were evaluated. RESULTS: Forty-four patients were treated with SMART at our institution from 2014 to 2019. Median follow-up from date of diagnosis was 16 months (range, 6.7-51.6). Late toxicity was limited to 2 (4.6%) grade 3 (gastrointestinal ulcers) and 3 (6.8%) grade 2 toxicities (duodenal perforation, antral ulcer, and gastric bleed). Tumor abutted OARs in 35 patients (79.5%) and tumor invaded OARs in 5 patients (11.1%). Reoptimization was performed for 93% of all fractions. Median overall survival was 15.7 months (95% confidence interval, 10.2-21.2), while 1-year and 2-year overall survival rates were 68.2% and 37.9%, respectively. One-year local control was 84.3%. CONCLUSIONS: This is the first reported experience using 50 Gy in 5 fractions for inoperable pancreatic cancer. SMART allows this ablative dose with promising outcomes while minimizing toxicity. Additional prospective trials evaluating efficacy and safety are warranted.
引用
- Hassanzadeh C, Rudra S, Bommireddy A, et al. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Adv Radiat Oncol. 2020. PMID: 33665480. doi:10.1016/j.adro.2020.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。